| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000023524 |
| Receipt No. | R000027082 |
| Scientific Title | Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients |
| Date of disclosure of the study information | 2016/08/08 |
| Last modified on | 2020/08/14 (Ver. 4) |
| Basic information | ||
| Public title | Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients | |
| Acronym | PD-L1 expression in immune cells and soluble PD-L1 in gastrointestinal cancer patients | |
| Scientific Title | Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients | |
| Scientific Title:Acronym | PD-L1 expression in immune cells and soluble PD-L1 in gastrointestinal cancer patients | |
| Region |
|
|
| Condition | |||
| Condition | Gastrointestinal Cancer
(Esophagial cancer,Gastric cancer, pancreatic cancer, liver cancer,billiary tract cancer, colorectal cancer) |
||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | PD-L1 expression in immune cells and soluble PD-L1 value in blood of various gastrointestinal cancer patients will be examined and their association with clinicopathological features of the diseases will be elucidated. |
| Basic objectives2 | Bio-availability |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Correlation between PD-L1 expression in immune cells and soluble PD-L1 value.
Correlation between PD-L1 expression in immune cells or soluble PD-L1 value and PD-L1 expression in tumor tissue. Characterstics of PD-L1 expression in immune cells or soluble PD-L1 value in each gastrointestinal cancer type. |
| Key secondary outcomes | PD-L1 expression in immune cells or blood soluble PD-L1 value as a new biomarker for specific clinico-pathological features in gastrointestinal cancers. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients diagnosed as esophagial cancer, gastric cancer, pancreatic cancer, billiary tract cancer, or colorectal cancer.
Patients who have agreed to provide their blood for this study. |
|||
| Key exclusion criteria | Patients who have not agreed to provide their blood for this study. | |||
| Target sample size | 70 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Jikei University School of Medicine | ||||||
| Division name | Division of Oncology | ||||||
| Zip code | 105-8461 | ||||||
| Address | 3-25-8 Nishi-shimbashi Minato-ku, Tokyo 105-8461 Japan | ||||||
| TEL | 03-3433-1111 | ||||||
| sahya@jikei.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Jikei University School of Medicine | ||||||
| Division name | Division of Oncology | ||||||
| Zip code | 105-8461 | ||||||
| Address | 3-25-8 Nishi-shimbashi Minato-ku, Tokyo 105-8461 Japan | ||||||
| TEL | 03-3433-1111 | ||||||
| Homepage URL | |||||||
| sahya@jikei.ac.jp | |||||||
| Sponsor | |
| Institute | Jikei University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Jikei University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Jikei University IRB |
| Address | 3-25-8 Nishi-shimbashi Minato-ku |
| Tel | +81334331111 |
| sahya@jikei.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | none |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | none | ||||||
| Number of participants that the trial has enrolled | 85 | ||||||
| Results | No results to be disclosed were obtained. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Patients of gastrointestinal(GI) cancer in Jikei University Hospital |
||||||
| Participant flow | Patients of GI cancer in Jikei University Hospital with agreement for the study were enrolled. |
||||||
| Adverse events | none |
||||||
| Outcome measures | Expression of PD-L1 in the immune cells, blood levels of sPD-L1 and the association between the above two in the patients of GI cancer. |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | PD-L1 expression in peripheral blood mononuclear cells will be examined by FACS, and amount of soluble PD-L1 in the patient blood will be determined by ELISA.Correlation of these results and the clinico-pathological features of the patients will be analyzed. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000027082 |